|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/15 | (2013.01) |
| A61K 31/13 | (2006.01) | ||
| A61K 39/21 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/167 | (2013.01) | ||
| A61K 31/136 | (2006.01) | ||
| A61K 31/18 | (2013.01) | ||
| C07K 14/16 | (2006.01) | ||
| C12Q 1/68 | (2018.01) | ||
| A61K 31/343 | (2013.01) | ||
| C12Q 1/70 | (2006.01) | ||
| A61K 31/395 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/4045 | (2013.01) | ||
| A61K 31/4184 | (2013.01) | ||
| A61K 31/167 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61K 31/18 | (2006.01) | ||
| A61K 39/39541 | (2013.01) | ||
| A61K 31/395 | (2006.01) | ||
| A61K 31/4406 | (2013.01) | ||
| A61K 31/4184 | (2006.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61K 31/506 | (2006.01) | ||
| C07K2317/76 | (2013.01) | ||
| A61K 31/343 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/4045 | (2006.01) | ||
| A61K 31/4406 | (2006.01) | ||
| A61K 38/15 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 3454844 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17796865.8 |
| Date of filing the European patent application | 2017-05-11 | |
| (97) | Date of publication of the European application | 2019-03-20 |
| (45) | Date of publication and mention of the grant of the patent | 2024-07-03 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/032218 |
| Date | 2017-05-11 |
| (87) | Number | WO 2017/197153 |
| Date | 2017-11-16 |
| (30) | Number | Date | Country code |
| 201662335044 P | 2016-05-11 | US | |
| 201662436361 P | 2016-12-19 | US |
| (72) |
BISSONNETTE, Reid, P. , US
ROLLAND, Alain , US
GILLINGS, Mireille , US
|
| (73) |
Huyabio International, LLC ,
12531 High Bluff Drive, Suite 138, San Diego, CA 92130,
US
|
| (54) | TREATMENT OF COLON CANCER WITH A COMBINATION OF THE HDAC INHIBITOR HBI-8000 AND A PD-L1 INHIBITOR |
| TREATMENT OF COLON CANCER WITH A COMBINATION OF THE HDAC INHIBITOR HBI-8000 AND A PD-L1 INHIBITOR |